BioCentury
ARTICLE | Clinical News

Gattex teduglutide: Phase III started

January 6, 2014 8:00 AM UTC

NPS began an open-label, international Phase III trial to evaluate 3 doses of subcutaneous teduglutide for 12 weeks in up to 36 pediatric patients with SBS who are dependent on parenteral support. Ted...